Chemotherapy and peripheral neuropathy
Authors:
- 26 August 2021
- journal article
- review article
- Published by Springer Nature in Neurological Sciences
- Vol. 42 (10) , 4109-4121
Abstract
Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major dose-limiting side effect of many anti-cancer agents, including taxanes, platinums, vinca alkaloids, proteasome inhibitors, immunomodulatory drugs, and antibody–drug conjugates. The resultant symptoms often persist post treatment completion and continue to impact on long-term function and quality of life for cancer survivors. At present, dose reduction remains the only strategy to prevent severe neuropathy, often leading clinicians to the difficult decision of balancing maximal treatment exposure and minimal long-lasting side effects. This review examines the clinical presentations of CIPN with each class of neurotoxic treatment, describing signs, symptoms, and long-term outcomes. We provide an update on the proposed mechanisms of nerve damage and review current data on clinical and genetic risk factors contributing to CIPN development. We also examine recent areas of research in the treatment and prevention of CIPN, with specific focus on current clinical trials and consensus recommendations for CIPN management.Keywords
Funding Information
- Cancer Institute NSW (14/TPG/1-05)
- National Health and Medical Research Council (1080521, 1148595)
- National Health and Medical Research Council (1132524, 1153439, 1156093)
This publication has 133 references indexed in Scilit:
- Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral NeuropathyClinical Cancer Research, 2012
- Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trialsSupportive Care in Cancer, 2012
- Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemiaJournal of Antimicrobial Chemotherapy, 2011
- Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1Journal of Clinical Oncology, 2011
- Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of ReversibilityThe Oncologist, 2011
- Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapyBreast Cancer Research and Treatment, 2010
- Treatment-related peripheral neuropathy in multiple myeloma: the challenge continuesThe Lancet Oncology, 2010
- Peripheral nerve damage associated with administration of taxanes in patients with cancerCritical Reviews in Oncology/Hematology, 2008
- Weekly Paclitaxel in the Adjuvant Treatment of Breast CancerNew England Journal of Medicine, 2008
- Bradycardia during therapy for multiple myeloma with thalidomideThe American Journal of Cardiology, 2004